新型胆囊收缩素受体拮抗剂CR 1392对大鼠蛙皮素诱导的急性胰腺炎的作用

Effect of a new cholecystokinin receptor antagonist CR 1392 on caerulein-induced acute pancreatitis in rats.

作者信息

Otsuki M, Tani S, Okabayshi Y, Nakamura T, Fujii M, Fujisawa T, Baba S, Itoh H

机构信息

Second Department of Internal Medicine, Kobe University School of Medicine, Japan.

出版信息

Pancreas. 1989;4(2):237-43. doi: 10.1097/00006676-198904000-00013.

DOI:10.1097/00006676-198904000-00013

PMID:2474165

Abstract

The effects of cholecystokinin receptor antagonist CR 1392 was studied in a model of mild acute pancreatitis induced in rats by four subcutaneous injections of the secretagogue caerulein. A single subcutaneous injection of 50 mg/kg body weight of CR 1392 caused a dramatic reduction in serum amylase concentration and pancreatic wet weight as well as histologic improvement of the caerulein-induced acute pancreatitis when given 30 min before the first caerulein injection. CR 1392 was also effective in reducing the elevated serum amylase activity, pancreatic weight, and histologic alterations even when administered after the pancreatitis had been induced. These present observations suggest that CR 1392 remains active for more than 3 h and blocks the action of caerulein on the pancreas.

摘要

在通过皮下四次注射促分泌素蛙皮素诱导大鼠发生轻度急性胰腺炎的模型中，研究了胆囊收缩素受体拮抗剂CR 1392的作用。在首次注射蛙皮素前30分钟皮下注射一次50毫克/千克体重的CR 1392，可使血清淀粉酶浓度和胰腺湿重显著降低，并使蛙皮素诱导的急性胰腺炎的组织学状况得到改善。即使在胰腺炎诱导后给药，CR 1392在降低血清淀粉酶活性升高、胰腺重量及组织学改变方面也同样有效。这些目前的观察结果表明，CR 1392的活性可持续超过3小时，并能阻断蛙皮素对胰腺的作用。